Literature DB >> 1701803

Interferon as an agent against herpes simplex virus.

M Ho1.   

Abstract

The effectiveness and limitations of interferon as an antiviral agent in man is exemplified by its actions against herpes simplex types 1 and 2. Given in adequate doses parenterally before or shortly after infection, interferon can ameliorate or reduce clinical manifestations or reduce the virus yield. It usually cannot completely prevent disease and may be particularly problematical if used late after infection in an acute disease. It is ineffective against the state of latent infection in ganglia. Interferon may have more potential in slower virus diseases and diseases in which other pathogenetic mechanisms affected by interferon's pleiotropic actions are operative.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701803     DOI: 10.1111/1523-1747.ep12875164

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  4 in total

1.  Alpha/Beta interferon and gamma interferon synergize to inhibit the replication of herpes simplex virus type 1.

Authors:  Bruno Sainz; William P Halford
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

2.  DNA vaccines encoding interleukin-8 and RANTES enhance antigen-specific Th1-type CD4(+) T-cell-mediated protective immunity against herpes simplex virus type 2 in vivo.

Authors:  J Sin; J J Kim; C Pachuk; C Satishchandran; D B Weiner
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

3.  Recognition of herpes simplex virus type 2 tegument proteins by CD4 T cells infiltrating human genital herpes lesions.

Authors:  D M Koelle; J M Frank; M L Johnson; W W Kwok
Journal:  J Virol       Date:  1998-09       Impact factor: 5.103

4.  Antigenic specificities of human CD4+ T-cell clones recovered from recurrent genital herpes simplex virus type 2 lesions.

Authors:  D M Koelle; L Corey; R L Burke; R J Eisenberg; G H Cohen; R Pichyangkura; S J Triezenberg
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.